Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants
Primary Purpose
Infant, Very Low Birth Weight
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Oropharyngeal administration of colostrums
Oropharyngeal administration of Normal saline
Sponsored by
About this trial
This is an interventional supportive care trial for Infant, Very Low Birth Weight focused on measuring oropharyngeal, breastmilk, colostrum, human milk, premature infant
Eligibility Criteria
Inclusion Criteria:
- Born weight≤1500g
- transferred to our hospital within 24 hours after birth
- the mother can provide colostrum
- parents of the infants agreed to participate in this study
Exclusion Criteria:
- The infants suffering from life-threatening conditions ,such as severe heart disease,whose survival time are expected <30d
- The infants suffering from any kinds of disease,which impact they take human milk by mouth.(such as gastrointestinal malformations, NEC, etc.)
human milk is contraindicated
An infant whose mother :
- Is infected with the human immunodeficiency virus (HIV)
- Is taking antiretroviral medications
- Has untreated active tuberculosis
- Is infected with human T-cell lymphotropic virus type l or ll
- Is using or dependent on an illicit drug except if the breastmilk is medically indicated
- Is taking prescribed cancer chemotherapy agents contraindicated for breastfeeding
- Is receiving any medications contraindicated in breast feeding
- Is receiving diagnostic or therapeutic radioactive isotopes or exposure to radioactive materials (for as long as they are radioactive in the milk)
- An infant diagnosed with galactosemia, a rare genetic metabolic disorder
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
colostrums
Normal saline
Arm Description
Oropharyngeal administration of colostrums, every 4 hours,continue for 7days
Oropharyngeal administration of Normal saline,every 4 hours,continue for 7days
Outcomes
Primary Outcome Measures
Change from Baseline in sIgA at 7 days
in urine and saliva
Change from Baseline in lactoferrin at 7 days
in urine and saliva
Change from Baseline in sIgA at 21 days
in urine and saliva
Change from Baseline in lactoferrin at 21 days
in urine and saliva
Secondary Outcome Measures
The duration from admission to the start of oral feeding
when the first time participants start bottle feeding by mouth(>5ml/once)
The duration from the start of enteric feeding to full enteric feeding
when the volume of milk participants take by mouth up to 140ml/kg/day
The number of participants with necrotizing enterocolitis (NEC)
Full Information
NCT ID
NCT02389478
First Posted
February 8, 2015
Last Updated
November 9, 2015
Sponsor
Children's Hospital of Fudan University
Collaborators
Fudan University
1. Study Identification
Unique Protocol Identification Number
NCT02389478
Brief Title
Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants
Official Title
Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants:Effects on Secretory Immunoglobulin A
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
March 2015 (undefined)
Primary Completion Date
October 2015 (Actual)
Study Completion Date
October 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital of Fudan University
Collaborators
Fudan University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to explore the effects of Oropharyngeal administration of colostrum to very low birth weight infants on sIgA and lactoferrin, in order to explore the protect immune function of colostrum to very low birth weight infants, to improve the utilization of breast milk and reduce infection rates of very low birth weight infants.
Detailed Description
The number of very low born weight infants increased every year.they are suffer from many questions.Recent studies have shown that Oropharyngeal administration of colostrum to very low birth weight infants can reduce the time reach full enteral nutrition .But there are no evidence support that it can promote infants' immune response. The hypothesis of the current study is that Oropharyngeal administration of colostrum to very low birth weight infants may increase the secretion of sIgA in urine and saliva.
The current study adopts randomized, double blind, controlled intervention trial, gives Oropharyngeal administration of colostrums to very low birth weight infants in intervention group and Oropharyngeal administration of Normal saline to control group. All indicators in this study are discrete traits, for sIgA、Lactoferrin number in Saliva and urine, number of CRP,time Begin oral feeding,time up to full enteral feeding, Person's chi-square tests were used for comparisons. For Blood culture results,The number of necrotizing enterocolitis (NEC) occurred, the investigators use Chi-square tests for comparisons between two groups. The study expects that Oropharyngeal administration of colostrum to very low birth weight infants can increase the secretion of sIgA in urine and saliva.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant, Very Low Birth Weight
Keywords
oropharyngeal, breastmilk, colostrum, human milk, premature infant
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
64 (Actual)
8. Arms, Groups, and Interventions
Arm Title
colostrums
Arm Type
Experimental
Arm Description
Oropharyngeal administration of colostrums, every 4 hours,continue for 7days
Arm Title
Normal saline
Arm Type
Other
Arm Description
Oropharyngeal administration of Normal saline,every 4 hours,continue for 7days
Intervention Type
Procedure
Intervention Name(s)
Oropharyngeal administration of colostrums
Other Intervention Name(s)
oral immune therapy
Intervention Description
rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
Intervention Type
Procedure
Intervention Name(s)
Oropharyngeal administration of Normal saline
Intervention Description
rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
Primary Outcome Measure Information:
Title
Change from Baseline in sIgA at 7 days
Description
in urine and saliva
Time Frame
at baseline(first time baby in hospital) and at 7 days
Title
Change from Baseline in lactoferrin at 7 days
Description
in urine and saliva
Time Frame
at baseline(first time baby in hospital) and at 7 days
Title
Change from Baseline in sIgA at 21 days
Description
in urine and saliva
Time Frame
at baseline(first time baby in hospital) and at 21 days
Title
Change from Baseline in lactoferrin at 21 days
Description
in urine and saliva
Time Frame
at baseline(first time baby in hospital) and at 21 days
Secondary Outcome Measure Information:
Title
The duration from admission to the start of oral feeding
Description
when the first time participants start bottle feeding by mouth(>5ml/once)
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 3 days
Title
The duration from the start of enteric feeding to full enteric feeding
Description
when the volume of milk participants take by mouth up to 140ml/kg/day
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 14 days
Title
The number of participants with necrotizing enterocolitis (NEC)
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
1 Month
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Born weight≤1500g
transferred to our hospital within 24 hours after birth
the mother can provide colostrum
parents of the infants agreed to participate in this study
Exclusion Criteria:
The infants suffering from life-threatening conditions ,such as severe heart disease,whose survival time are expected <30d
The infants suffering from any kinds of disease,which impact they take human milk by mouth.(such as gastrointestinal malformations, NEC, etc.)
human milk is contraindicated
An infant whose mother :
Is infected with the human immunodeficiency virus (HIV)
Is taking antiretroviral medications
Has untreated active tuberculosis
Is infected with human T-cell lymphotropic virus type l or ll
Is using or dependent on an illicit drug except if the breastmilk is medically indicated
Is taking prescribed cancer chemotherapy agents contraindicated for breastfeeding
Is receiving any medications contraindicated in breast feeding
Is receiving diagnostic or therapeutic radioactive isotopes or exposure to radioactive materials (for as long as they are radioactive in the milk)
An infant diagnosed with galactosemia, a rare genetic metabolic disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhang YuXia, doctor
Organizational Affiliation
Children Hospital of Fudan University
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
18769379
Citation
Rodriguez NA, Meier PP, Groer MW, Zeller JM. Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives. J Perinatol. 2009 Jan;29(1):1-7. doi: 10.1038/jp.2008.130. Epub 2008 Sep 4.
Results Reference
background
Learn more about this trial
Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants
We'll reach out to this number within 24 hrs